The potential of circHIPK3 as a biomarker in chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by leukocytosis and left shift. The primary molecular alteration is the BCR::ABL1, chimeric oncoprotein with tyrosine kinase activity, responsible for the initial oncogenesis of the disease. Therapy of CML was revolutioniz...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1330592/full |
| _version_ | 1797277259968544768 |
|---|---|
| author | Eduardo Wandame Gomez Eduardo Wandame Gomez Laura Berti De Paula Rafael Diogo Weimer Alessandra Helena da Silva Hellwig Grazielle Motta Rodrigues Ana Paula Alegretti Jarbas Rodrigues de Oliveira |
| author_facet | Eduardo Wandame Gomez Eduardo Wandame Gomez Laura Berti De Paula Rafael Diogo Weimer Alessandra Helena da Silva Hellwig Grazielle Motta Rodrigues Ana Paula Alegretti Jarbas Rodrigues de Oliveira |
| author_sort | Eduardo Wandame Gomez |
| collection | DOAJ |
| description | Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by leukocytosis and left shift. The primary molecular alteration is the BCR::ABL1, chimeric oncoprotein with tyrosine kinase activity, responsible for the initial oncogenesis of the disease. Therapy of CML was revolutionized with the advent of tyrosine kinase inhibitors, but it is still not considered curative and may present resistance and serious adverse effects. Discoveries in CML inaugurated a new era in cancer treatment and despite all the advances, a new biomarker is needed to detect resistance and adverse effects. Circular RNAs (circRNAs) are a special type of non-coding RNA formed through a process called backsplicing. The majority of circRNAs are derived from protein-coding genes. CircHIPK3 is formed from the second exon of the HIPK3 gene and has been found in various pathologies, including different types of cancer. New approaches have demonstrated the potential of circular RNAs in cancer research, and circHIPK3 has shown promising results. It is often associated with cellular regulatory pathways, suggesting an important role in the molecular dynamics of tumors. The identification of biomarkers is an important tool for therapeutic improvement; thus we review the role of circHIPK3 and its potential as a biomarker in CML. |
| first_indexed | 2024-03-07T15:46:05Z |
| format | Article |
| id | doaj.art-ff40ab57c04a4fbb88cc047953b1d608 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-07T15:46:05Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-ff40ab57c04a4fbb88cc047953b1d6082024-03-05T04:37:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-03-011410.3389/fonc.2024.13305921330592The potential of circHIPK3 as a biomarker in chronic myeloid leukemiaEduardo Wandame Gomez0Eduardo Wandame Gomez1Laura Berti De Paula2Rafael Diogo Weimer3Alessandra Helena da Silva Hellwig4Grazielle Motta Rodrigues5Ana Paula Alegretti6Jarbas Rodrigues de Oliveira7Laboratory of Cell Biophysics and Inflammation, School of Health and Life Sciences, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, BrazilLaboratory of Molecular Biology, Laboratory Diagnostic Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, BrazilLaboratory of Cell Biophysics and Inflammation, School of Health and Life Sciences, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, BrazilLaboratory of Cell Biophysics and Inflammation, School of Health and Life Sciences, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, BrazilLaboratory of Molecular Biology, Laboratory Diagnostic Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, BrazilLaboratory of Molecular Biology, Laboratory Diagnostic Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, BrazilLaboratory of Molecular Biology, Laboratory Diagnostic Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, BrazilLaboratory of Cell Biophysics and Inflammation, School of Health and Life Sciences, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, BrazilChronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by leukocytosis and left shift. The primary molecular alteration is the BCR::ABL1, chimeric oncoprotein with tyrosine kinase activity, responsible for the initial oncogenesis of the disease. Therapy of CML was revolutionized with the advent of tyrosine kinase inhibitors, but it is still not considered curative and may present resistance and serious adverse effects. Discoveries in CML inaugurated a new era in cancer treatment and despite all the advances, a new biomarker is needed to detect resistance and adverse effects. Circular RNAs (circRNAs) are a special type of non-coding RNA formed through a process called backsplicing. The majority of circRNAs are derived from protein-coding genes. CircHIPK3 is formed from the second exon of the HIPK3 gene and has been found in various pathologies, including different types of cancer. New approaches have demonstrated the potential of circular RNAs in cancer research, and circHIPK3 has shown promising results. It is often associated with cellular regulatory pathways, suggesting an important role in the molecular dynamics of tumors. The identification of biomarkers is an important tool for therapeutic improvement; thus we review the role of circHIPK3 and its potential as a biomarker in CML.https://www.frontiersin.org/articles/10.3389/fonc.2024.1330592/fullchronic myeloid leukemiabiomarkerncRNAcircRNACircHIPK3 |
| spellingShingle | Eduardo Wandame Gomez Eduardo Wandame Gomez Laura Berti De Paula Rafael Diogo Weimer Alessandra Helena da Silva Hellwig Grazielle Motta Rodrigues Ana Paula Alegretti Jarbas Rodrigues de Oliveira The potential of circHIPK3 as a biomarker in chronic myeloid leukemia Frontiers in Oncology chronic myeloid leukemia biomarker ncRNA circRNA CircHIPK3 |
| title | The potential of circHIPK3 as a biomarker in chronic myeloid leukemia |
| title_full | The potential of circHIPK3 as a biomarker in chronic myeloid leukemia |
| title_fullStr | The potential of circHIPK3 as a biomarker in chronic myeloid leukemia |
| title_full_unstemmed | The potential of circHIPK3 as a biomarker in chronic myeloid leukemia |
| title_short | The potential of circHIPK3 as a biomarker in chronic myeloid leukemia |
| title_sort | potential of circhipk3 as a biomarker in chronic myeloid leukemia |
| topic | chronic myeloid leukemia biomarker ncRNA circRNA CircHIPK3 |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1330592/full |
| work_keys_str_mv | AT eduardowandamegomez thepotentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT eduardowandamegomez thepotentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT laurabertidepaula thepotentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT rafaeldiogoweimer thepotentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT alessandrahelenadasilvahellwig thepotentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT graziellemottarodrigues thepotentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT anapaulaalegretti thepotentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT jarbasrodriguesdeoliveira thepotentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT eduardowandamegomez potentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT eduardowandamegomez potentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT laurabertidepaula potentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT rafaeldiogoweimer potentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT alessandrahelenadasilvahellwig potentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT graziellemottarodrigues potentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT anapaulaalegretti potentialofcirchipk3asabiomarkerinchronicmyeloidleukemia AT jarbasrodriguesdeoliveira potentialofcirchipk3asabiomarkerinchronicmyeloidleukemia |